Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO, Aug. 21, 2018 /PRNewswire/ — Agena Bioscience (Agena) announced today that they have entered into a collaboration with PerkinElmer, incorporating the LabChip® GX Touch™ nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassARRAY® system. The companies have focused on targeting …
Tag Archives: liquid biopsy
August, 2018
-
6 August
Biocept to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
SAN DIEGO, Aug. 6, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to …
July, 2018
-
26 July
Personal Genome Diagnostics’ PGDx elio Plasma Resolve Receives Breakthrough Device Designation from the FDA
BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leading cancer genomics company and pioneer in liquid biopsy, today announced that PGDx elio™ plasma resolve has received Breakthrough Device designation from The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). PGDx elio™ plasma resolve is …
-
25 July
Biocept and UC San Diego Moores Cancer Center Partner to Study Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
SAN DIEGO, July 23, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with …
January, 2018
-
18 January
MDxHealth Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients
HERSTAL, BELGIUM and IRVINE, CA, January 18, 2018 – MDxHealth SA (“MDxHealth, or the “Company”), (Euronext: Brussels MDXH.BR), an international healthcare company, developing and offering molecular diagnostic tests to personalize the diagnosis and treatment of urologic cancer, today announced promising research results with a new liquid biopsy test in development. Data from this …
-
11 January
Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Detection of Lung Cancer Biomarkers
SAN DIEGO, Jan. 9, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporation of the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument into the …
February, 2017
-
1 February
MD Anderson and Guardant Health Partner to Make Comprehensive Liquid Biopsy an Oncology Standard of Care
MD Anderson News Release 01/31/2017 The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment. The commercial, research and development agreement will make MD Anderson among the few hospitals …
September, 2016
-
12 September
Case for Liquid Biopsies Builds in Advanced Lung Cancer
PHILADELPHA— For patients with advanced lung cancer, a non-invasive liquid biopsy may be a more effective and suitable alternative to the gold standard tissue biopsy to detect clinically relevant mutations and help guide their course of treatment, suggests a new study published this week in the journal Clinical Cancer Research …
June, 2016
-
24 June
Epic Sciences’ Liquid Biopsy Test Matches Patients with PARP Inhibitors
SAN DIEGO, June 24, 2016 /PRNewswire/ — Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs). The new test has already been incorporated into numerous clinical studies of HRD-targeted therapeutics in …
January, 2016
-
5 January
New Blood Test Technology Promising for Guiding Treatment Decisions in Prostate Cancer
ALEXANDRIA, Va. – An early study suggests that an experimental new blood test may help guide individualized decisions on the most appropriate treatments for patients with prostate cancer. The new non-invasive “liquid biopsy” scans the entire landscape of different kinds of cancer cells in blood and analyzes their appearance (e.g., …